The mtor inhibitor rapamycin protects from premature cellular senescence early after experimental kidney transplantation

HIGHLIGHTS

• who: Uwe Hoff and collaborators from the Institute of Pathology, Medical School, Germany, Vitanas for Geriatric Editor:, Universidade have published the paper: The mTOR inhibitor Rapamycin protects from premature cellular senescence early after experimental kidney transplantation, in the Journal: PLOS ONE of 24/05/2021
• future: Reduced senescence might maintain the renal regenerative capacity rendering resilience to future injuries resulting in protection from interstitial fibrosis and tubular atrophy.

SUMMARY

Despite improvements in short-term outcomes after kidney transplantation due to lower rates of acute rejection little progress has been made with . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.